OBJECTIVES:  To conduct a literature review and concept elicitation interviews generating supportive evidence for multiple myeloma (MM) clinical trial PRO selection incorporating direct patient disease experience. METHODS:  A provisional conceptual model was developed from a literature review (2005‑2015) of studies which included signs, symptoms, and functional impacts of MM. Concept mapping was against EORTC QLQ-C30, EORTC QLQ-MY20, FACT-MM, FACT-Anemia, FACIT Fatigue Scale, and BFI. A qualitative, cross-sectional study confirmed key symptoms and impacts from the literature review. Concept elicitation telephone interviews were conducted with 10 US patients (4 sites) using a semi-structured discussion guide. Thematic content analysis on interview transcripts was performed using qualitative software (ATLAS.ti). Results were incorporated into the concept mapping exercise and the conceptual model was revised. RESULTS:  In 44 articles, 21 symptoms/signs and 23 functional impacts were identified. 13/44 studies used EORTC QLQ-C30 for symptom and functional impacts. Interview sample included newly diagnosed (5), relapsed refractory (RR; 4), and maintenance (1) non-Hispanic White patients (mean 65 years; range 52-78). Patients endorsed all 23 impacts and 22 symptoms, 16 were in the literature and 6 were new. 90% endorsed fatigue, pain; 70% endorsed bone pain, back pain, pain elsewhere, hematologic abnormalities. EORTC QLQ-C30 covered 10 symptoms/17 impacts; EORTC QLQ-MY20 an additional 7 symptoms/4 impacts. FACT-MM included comparable symptoms, and 19 impacts but no activities of daily living (ADLs or IADLs) unlike EORTC-QLQ-C30. FACT-An and FACIT Fatigue covered anemia and fatigue-related symptoms and impacts more than other instruments including BFI. CONCLUSIONS:  EORTC QLQ-C30 generally supported the conceptual model with enhanced coverage with MY20. Endorsement of fatigue by newly diagnosed and RRMM patients indicates that this is not treatment-related alone. This population could benefit from FACT-An or FACIT Fatigue Scale in future trials to provide better coverage. Quantitative research will further enable PRO selection to fit the purpose of clinical studies.